Health services and systems
New York Times | 22 hours ago
Health insurance companies are no longer allowed to turn away patients because of their pre-existing conditions or charge them more because of those conditions. But some health policy experts say insurers may be doing so in a more subtle way: by forcing people with a variety of illnesses — including Parkinson’s disease, diabetes and epilepsy — to pay more for their drugs.
New and experimental HIV treatments
Newswire.ca | 23 hours ago
Janssen Inc. announced today that PREZCOBIX™ (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. The new treatment option combining a protease inhibitor with a boosting agent reduces the number of pills required to manage HIV.
New York Times | 23 hours ago
Scott Wiener, a member of the San Francisco Board of Supervisors, made an unusual public announcement on Wednesday: He takes Truvada, a daily antiviral pill, to greatly reduce his risk of contracting HIV.
Poz | 17 September 2014
“HIV Treatment Works” is a new awareness campaign from the U.S. Centers for Disease Control and Prevention (CDC).
Hepatitis C treatment
HIVandhepatitis.com | 17 September 2014
A coalition of hepatitis C advocacy organizations and medical providers has issued an open letter to the Secretary of Health and Human Services calling for an end to restrictions on access to hepatitis C treatment by private insurers and public payers seeking to avoid the cost of newly approved direct-acting antivirals. HIV medical providers also called for reducing barriers to treatment, including restrictions on which medical specialists may treat people with hepatitis C.
Behaviour change interventions
Positive Lite | 17 September 2014
The most important group who should hear about treatment as prevention, undetectability, sero-sorting and all the other non-condom options, are those who have successfully avoided HIV thus far and are reluctant to get tested. In other words the vast majority of the LGBT population, because they are the ones who are getting the wrong end of the stick when they hear snippets of information about HIV.
Infojustice | 17 September 2014
Gilead’s proposed license, and its limitations, is important because Gilead has applied for patents on Sovaldi® and ledipasvir in many countries, although a number of countries in the probable licensed territory are without patents. As a patent holder, Gilead generally has rights to exclude competitors and charge monopoly prices on these life-saving medicines. The anticipated license will set precise terms on which companies can make generic equivalents and where and under what circumstances those generics can be sold. In other words, Gilead sits in the driver’s seat and has enormous power to decide who does and doesn’t get more affordable access to generics of assured quality.
Hepatitis C treatment
I-MAK | 17 September 2014
Gilead is excluding 51 middle income countries (MICs) from its license for sofosbuvir, an oral hepatitis C drug. Across these MICs, where nearly 50 million people are infected with hepatitis C virus (HCV), lack of access to generic sofosbuvir will increase the total cost of curing hepatitis C by an estimated $60 billion dollars, according to I-MAK’s analysis.
EATG | 17 September 2014
We are writing to express our astonishment and concern regarding your decision to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of internal market and industry within the new Commission.
How HIV causes disease
Science Daily | 17 September 2014
We respond to infections in two fundamental ways. One is 'resistance,' where the body attacks the invading pathogen and reduces its numbers. Another, which is much less well understood, is 'tolerance,' where the body tries to minimize the damage done by the pathogen. A study using data from a large Swiss cohort of HIV-infected individuals gives us a glimpse into why some people cope with HIV better than others.